Literature DB >> 30515798

Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.

Nasser Hashemi Goradel1, Nasir Mohajel2, Ziba Veisi Malekshahi1, Samira Jahangiri3, Masoud Najafi4, Bagher Farhood5, Keywan Mortezaee6, Babak Negahdari1, Arash Arashkia2.   

Abstract

Cancer therapy using oncolytic viruses is an emerging area, in which viruses are engineered to selectively propagate in tumor tissues without affecting healthy cells. Because of the advantages that adenoviruses (Ads) have over other viruses, they are more considered. To achieve tumor selectivity, two main modifications on Ads genome have been applied: small deletions and insertion of tissue- or tumor-specific promoters. Despite oncolytic adenoviruses ability in tumor cell lysis and immune responses stimulation, to further increase their antitumor effects, genomic modifications have been carried out including insertion of checkpoint inhibitors and antigenic or immunostimulatory molecules into the adenovirus genome and combination with dendritic cells and chemotherapeutic agents. This study reviews oncolytic adenoviruses structures, their antitumor efficacy in combination with other therapeutic strategies, and finally challenges around this treatment approach.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  adenovirus; dendritic cells; immune responses; oncolytic viruses; tumor

Mesh:

Substances:

Year:  2018        PMID: 30515798     DOI: 10.1002/jcp.27850

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  21 in total

Review 1.  Key promoters of tumor hallmarks.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Int J Clin Oncol       Date:  2021-11-13       Impact factor: 3.402

Review 2.  Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Cell Oncol (Dordr)       Date:  2022-05-19       Impact factor: 7.051

Review 3.  Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy.

Authors:  Hee Seung Seo; Chi-Pin James Wang; Wooram Park; Chun Gwon Park
Journal:  Tissue Eng Regen Med       Date:  2021-10-01       Impact factor: 4.451

Review 4.  Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer.

Authors:  Momeneh Ghanaat; Nasser Hashemi Goradel; Arash Arashkia; Nasim Ebrahimi; Sajjad Ghorghanlu; Ziba Veisi Malekshahi; Esmail Fattahi; Babak Negahdari; Hami Kaboosi
Journal:  Acta Pharmacol Sin       Date:  2021-02-25       Impact factor: 6.150

5.  "Double-punch" strategy for delivery of viral immunotherapy with prolonged tumor retention and enhanced transfection efficacy.

Authors:  Juan Wang; Chunqing Guo; Xiang-Yang Wang; Hu Yang
Journal:  J Control Release       Date:  2020-12-02       Impact factor: 9.776

Review 6.  Targeting of cancer cell death mechanisms by resveratrol: a review.

Authors:  Xiao Fu; Mu Li; Cuilian Tang; Zezhi Huang; Masoud Najafi
Journal:  Apoptosis       Date:  2021-09-25       Impact factor: 4.677

Review 7.  Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer.

Authors:  Anna Maria Malfitano; Sarah Di Somma; Nella Prevete; Giuseppe Portella
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

Review 8.  Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.

Authors:  Meijun Zheng; Jianhan Huang; Aiping Tong; Hui Yang
Journal:  Mol Ther Oncolytics       Date:  2019-11-02       Impact factor: 7.200

9.  Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model.

Authors:  Mariangela Garofalo; Laura Bertinato; Monika Staniszewska; Magdalena Wieczorek; Stefano Salmaso; Silke Schrom; Beate Rinner; Katarzyna Wanda Pancer; Lukasz Kuryk
Journal:  Pharmaceutics       Date:  2021-04-14       Impact factor: 6.321

Review 10.  Oncolytic Adenovirus-A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC.

Authors:  Mubalake Abudoureyimu; Yongting Lai; Chuan Tian; Ting Wang; Rui Wang; Xiaoyuan Chu
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.